NCT06644378View on ClinicalTrials.gov

A Study of [14C]-LY3866288 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

January 3, 2025

Study Completion Date

January 3, 2025

Conditions
Healthy
Interventions
DRUG

[14C]-LY3866288

Administered orally.

DRUG

LY3866288

Administered orally.

DRUG

[14C]-LY3866288

Administered IV.

Trial Locations (1)

53704

Fortrea Clinical Research Unit, Madison

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06644378 - A Study of [14C]-LY3866288 in Healthy Participants | Biotech Hunter | Biotech Hunter